Status:
COMPLETED
Measurement for Viral Reservoir and Immune Function in HIV-1-infected Patients Under Antiretroviral Therapy
Lead Sponsor:
National Taiwan University Hospital
Conditions:
HIV-1-infection
Eligibility:
All Genders
20-50 years
Brief Summary
Current antiretroviral therapy (ART) is highly effective to suppress plasma viral load to below the detection limit and to restore the host immunity, thus to prolong the survival of HIV-1-infected pat...
Detailed Description
Introduction Current antiretroviral therapy (ART) is highly effective to suppress plasma viral load to below the detection limit and to restore the host immunity, thus to prolong the survival of HIV-...
Eligibility Criteria
Inclusion
- Confirmed HIV-1-infected patients
- 20-50 years old
- receiving antiretroviral therapy
Exclusion
- Serious co-morbidity
- Obvious hepatic or renal dysfunction
- Receiving immunosuppressive therapy
Key Trial Info
Start Date :
January 28 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 5 2022
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT04068441
Start Date
January 28 2017
End Date
September 5 2022
Last Update
October 17 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taiwan, 100